We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Srp7.0
Serrapeptase Research
Mostly mechanism / observationalModerate safety
10 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Serrapeptase studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2013–2026 with a typical study size of 90 participants.
Based on 10 studies · 1 meta-analysis · 2 RCTs · 571 total participants
InflammationReduced swelling and inflammation · 1-2 weeks
Mostly mechanism / observational4 studies
Pain & analgesia
Mostly mechanism / observational3 studies
Safety profile
Mostly mechanism / observational3 studies
Therapeutic & clinical
Too few graded studies2 studies
Heart & blood pressure
Too few graded studies2 studies
By the numbers
Pulled from 7 studies with measurable effects
People studied
571
typical study: 90 people
Strongest designs
3
1 pooled, 2 randomised
Populations Studied
Cardiovascular patients1
Patients with blood thrombi1
Various conditions1
patients with inflammatory conditions1
Active research area
6 studies in the last 5 years · Latest meta-analysis: 2021
201320192026
1Serratiopeptidase therapeutic applications and improvementsSystematic ReviewCited 1×2024
Hosseini SB et al. · Archives of microbiology (2024)
To overcome such limitations, improved versions of the enzyme were introduced using protein engineering in our previous studies.
Novel functional serratiopeptidases with shorter length and higher stability have seemingly created a hope for using this enzyme as a more effective therapeutic enzyme.
2Serratiopeptidase therapeutic and clinical applicationsSystematic ReviewCited 24×2022
In addition, the review highlights the therapeutic and clinical aspects of the serratiopeptidase enzyme to combat COVID-19-induced respiratory syndrome.
Nair SR et al. · Biomolecules (2022)
Existing serratiopeptidase treatments in combination with antibiotics are popular in the treatment of postoperative swelling.
Although an exclusive number of serratiopeptidase-producing strains have been derived, there is an urge for new recombinant strains to enhance the production of the enzyme.
This review explores the properties of serratiopeptidase, different therapeutic aspects, industrial production, and various analytical techniques used in enzyme recovery.
This review is the first to cover all the natural and recombinant thrombolytic agents used in enzyme therapy.
Kotb E · Biotechnology progress (2014)
According to data provided by the World Health Organization (WHO) in 2000, heart diseases are responsible for 29% of the total mortality rate in the world.
Furthermore, recombinant DNA technology has succeeded in improving and decreasing the undesirable effects of the first generation of enzymes.
This review is the first to cover all the natural and recombinant thrombolytic agents used in enzyme therapy.
Oral serrapeptase supplementation did not demonstrate measurable efficacy in preventing postoperative fibrosis or improving patient-reported outcomes following liposuction for lipedema.
Bruno A et al. · Aesthetic plastic surgery (2026)
No statistically significant differences were observed in the primary outcome of tissue stiffness at 4 weeks (14.8 ± 3.1 kPa vs. 15.2 ± 3.0 kPa; p = 0.62) or 3 months (13.7 ± 2.9 kPa vs. 14.0 ± 3.2 kPa; p = 0.78).
Oral serrapeptase supplementation did not demonstrate measurable efficacy in preventing postoperative fibrosis or improving patient-reported outcomes following liposuction for lipedema.
These findings do not support its routine use in this clinical setting.